Pembrolizumab-induced thrombotic thrombocytopenic purpura.

Introduction: Pembrolizumab is a humanised monoclonal antibody targeting the receptor programmed cell death protein-1 (PD-1), with anti-tumour activity demonstrated for many malignancies. Such immune checkpoint inhibitors are associated with many immune-related adverse events including rash, colitis, hepatitis, pneumonitis, endocrinopathy and, rarely, haematological adverse events, including immune-related thrombocytopenia.

Case Report: We report a 60-year-old female with metastatic non-small cell lung cancer treated with pembrolizumab every three weeks.